Camlin Fine Sciences
Financials
Estimates*
INR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 10.4b | 11.8b | 14.1b | 16.8b | 16.0b | 18.8b | 20.7b |
% growth | 17 % | 13 % | 19 % | 19 % | (5 %) | 18 % | 10 % |
EBITDA | 1.2b | 1.9b | 1.8b | 2.1b | 1.2b | 2.1b | 2.6b |
% EBITDA margin | 11 % | 16 % | 13 % | 13 % | 7 % | 11 % | 13 % |
Profit | 303m | 510m | 607m | 521m | (928m) | 503m | 853m |
% profit margin | 3 % | 4 % | 4 % | 3 % | (6 %) | 3 % | 4 % |
EV / revenue | 0.5x | 1.5x | 1.6x | 1.2x | 0.9x | 0.9x | 0.8x |
EV / EBITDA | 4.1x | 9.4x | 12.2x | 9.5x | 12.6x | 8.3x | 6.6x |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
INR1.8b | Post IPO Equity | ||
* | €20.0m | Post IPO Equity | |
Total Funding | - |
Recent News about Camlin Fine Sciences
EditCamlin Fine Sciences (CFS) operates in the specialty chemicals sector, providing high-quality chemical solutions for various industries. The company serves clients in sectors such as food, pharmaceuticals, petrochemicals, and animal nutrition. CFS operates globally with a significant presence in North America, Europe, and Asia. The business model revolves around manufacturing and supplying specialty chemicals, including antioxidants, aroma chemicals, and performance chemicals. Revenue is generated through long-term supply agreements and joint ventures, such as the partnership with Lockheed Martin for advanced energy storage solutions and a joint venture with Pahang Pharma for animal nutrition. CFS's greenfield expansion in Dahej SEZ and its vertical integration strategy enhance its production capabilities and market reach. The company is also committed to corporate social responsibility, focusing on healthcare, education, and environmental sustainability.
Keywords: specialty chemicals, antioxidants, aroma chemicals, performance chemicals, energy storage, animal nutrition, global presence, joint ventures, vertical integration, sustainability.